After Molecular Partners AG reported an 78% reduction of hospitalisation by a single ensovibep dose in infected COVID-19 patients, Novartis AG is to pay a CHF150m milestone.
Neurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006.
Swiss Santhera Pharmaceuticals has entered into a $124m licence deal with Chinese Sperogenix Therapeuticis to market its DMD drug vamorolone.
Moderna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax.
Novo Holdings, together with Saminvest, Vækstfonden, the European Investment Fund and its three co-founders have put €110m in the first fund of Sound Bioventures AB.
The new year begins with good news.
Novo Holdings is set to invest €86m in 21st.BIO A/S – a new Danish bioindustrial scale-up company – to boost the production of proteins.
Ocular gene therapy specialist Gyroscope Therapeutics Holdings plc is to be acquired by Novartis AG for up to $1.5bn.
Dutch metabolic disease specialist NorthSea Therapeutics NV has baged US$80m in a Series C fundraising co-led by Ysios Capital and Forbion Growth.
French-British magnetic trap specialist Depixus has raised €30,6m to develop a commercial instrument based on the company’s MAGNA technology.